Rexahn Pharmaceuticals.Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.
CLICK HERE FOR FULL ANLAYSIS OF REXAHN PHARMACEUTICALS
Tuesday, September 21, 2010
Rexahn says study shows neuroprotective effects of clavulanic acid, main ingredient in Seradaxin drug
Clinical stage pharma company Rexahn Pharmaceuticals (NYSE Amex: RNN) said Tuesday that a published Drug Development Research article indicates that clavulanic acid, the active ingredient of the company's lead central nervous system drug Seradaxin, protects neurons from brain damage associated with neurodegnerative disease.
In the study, rodents that were exposed to different neurotoxins, were administered with clavulanic acid, which protected neurons in the hippocampus and dopaminergic regions of the brain that are critical in Alzheimer's and Parkinson's disease, respectively.
"The exciting neuronal protective properties of clavulanic acid make it a highly promising treatment for neuronal cell death diseases like Parkinson's and Alzheimer's," said Rexahn CEO Chang Ahn.
Parkinson's disease afflicts five million people worldwide, and with the aging of the baby boom generation, that population is expected to double by 2030.
According to the Alzheimer's Association, by 2050, the number of Americans aged 65 and older with Alzheimer's is projected to reach between 11 million and 16 million, unless medical breakthroughs can prevent or more effectively treat the disease.
Currently, Alzheimer's and Parkinson's therapies only provide symptomatic relief.
"Clavulanic acid has breakthrough potential of shielding the brain cell survival mechanisms, rather than fighting one-by-one the multitude of triggers that can activate the cell death mechanisms common in Alzheimer's and Parkinson's," added Ahn.
Alzheimer's has at least five major triggers, while Parkinson's has three major dysfunctioning mechanisms. Rather than intercepting and fighting each trigger, clavulanic acid has shown to broadly protect brain cell mechanisms.
Rexahn develops and commercializes therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. The company currently has three drug candidates in Phase II clinical trials, including Archexin, Serdaxin, and Zoraxel.
The company rallied more than 3% Tuesday morning, to trade at $1.24 on NYSE Amex Exchange.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL THIS STOCK !!!!!!!!!!!!!!!
For more information contact Senior Solutions at (954) 456-8984 or toll free at 1-800-213-3524
No comments:
Post a Comment